ATE193447T1 - Verfahren zur hemmung der karzinogenese durch behandlung mit dehydroepiandrosteron und dessen analoge - Google Patents

Verfahren zur hemmung der karzinogenese durch behandlung mit dehydroepiandrosteron und dessen analoge

Info

Publication number
ATE193447T1
ATE193447T1 AT93906193T AT93906193T ATE193447T1 AT E193447 T1 ATE193447 T1 AT E193447T1 AT 93906193 T AT93906193 T AT 93906193T AT 93906193 T AT93906193 T AT 93906193T AT E193447 T1 ATE193447 T1 AT E193447T1
Authority
AT
Austria
Prior art keywords
dhea
analog
dehydroepiandrosterone
analogues
treating
Prior art date
Application number
AT93906193T
Other languages
English (en)
Inventor
Jonathan W Nyce
Original Assignee
Univ East Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ East Carolina filed Critical Univ East Carolina
Application granted granted Critical
Publication of ATE193447T1 publication Critical patent/ATE193447T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AT93906193T 1992-02-24 1993-02-23 Verfahren zur hemmung der karzinogenese durch behandlung mit dehydroepiandrosteron und dessen analoge ATE193447T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84051092A 1992-02-24 1992-02-24
PCT/US1993/001637 WO1993016704A1 (en) 1992-02-24 1993-02-23 Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof

Publications (1)

Publication Number Publication Date
ATE193447T1 true ATE193447T1 (de) 2000-06-15

Family

ID=25282563

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93906193T ATE193447T1 (de) 1992-02-24 1993-02-23 Verfahren zur hemmung der karzinogenese durch behandlung mit dehydroepiandrosteron und dessen analoge

Country Status (9)

Country Link
US (1) US5527789A (de)
EP (1) EP0627921B1 (de)
JP (1) JPH07504198A (de)
AT (1) ATE193447T1 (de)
AU (1) AU676470B2 (de)
CA (1) CA2117532C (de)
DE (1) DE69328771T2 (de)
ES (1) ES2146228T3 (de)
WO (1) WO1993016704A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US7893044B2 (en) 1995-02-24 2011-02-22 Epigenesis Pharmaceutical, Inc. Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrosterone
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
AU4127499A (en) * 1998-06-11 1999-12-30 Endorecherche Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta-diol
US6048886A (en) * 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
DE60045751D1 (de) 1999-09-30 2011-04-28 Harbor Biosciences Inc Therapeutische Behandlung androgenrezeptorbedingter Leiden
US7241753B2 (en) 2000-02-25 2007-07-10 Loria Roger M Method of treatment of prostate cancer
AUPR177300A0 (en) * 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
WO2002085297A2 (en) * 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
AU2002303425A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
BR0311883A (pt) * 2002-06-17 2005-04-05 Epigenesis Pharmaceuticals Llc Recipiente selado, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento da doença pulmonar obstrutiva crÈnica, para a redução ou exaustão da adenosina em um tecido do paciente e para profilaxia ou tratamento de um distúrbio ou condição associada com nìveis altos de adenosina ou sensibilidade à adenosina em um tecido do paciente
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
KR20160106194A (ko) * 2004-01-22 2016-09-09 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
US20050222049A1 (en) * 2004-03-31 2005-10-06 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20050227927A1 (en) * 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20090317477A1 (en) * 2004-03-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
CA2680825C (en) 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
CN102083424B (zh) 2008-04-11 2013-08-28 细胞研究有限公司 诱导癌细胞凋亡的方法和应用
US20140024022A1 (en) * 2009-02-09 2014-01-23 Nihon Kohden Corporation Cell treatment solution and method of preparing stained cell suspension for a measurement of nuclear dna by flow cytometry
BRPI1010648A2 (pt) 2009-05-11 2016-03-15 Berg Biosystems Llc métodos para o diagnóstico de distúrbios oncológicos usando transferidores epimetabólicos, moléculas intracelulares multidimensionais ou influenciadores ambientais
CA2791693C (en) 2010-03-12 2018-11-27 Niven Rajin Narain Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
KR101933732B1 (ko) 2011-04-04 2018-12-28 버그 엘엘씨 중추 신경 시스템 종양들의 치료 방법
SG10201605008TA (en) 2011-06-17 2016-07-28 Berg Llc Inhalable pharmaceutical compositions
US20130064815A1 (en) * 2011-09-12 2013-03-14 The Trustees Of Princeton University Inducing apoptosis in quiescent cells
CA2909094C (en) 2013-04-08 2023-06-27 Berg Llc Methods for the treatment of cancer using coenzyme q10 combination therapies
EP3730131A1 (de) 2013-09-04 2020-10-28 Berg LLC Verfahren zur behandlung von krebs mittels kontinuierlicher infusion von coenzym q10
TW201831436A (zh) * 2017-02-24 2018-09-01 郭盈妤 分離自牛樟芝的化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US5001119A (en) * 1987-11-25 1991-03-19 Schwartz Arthur G 16-substituted androstanes and 16-substituted androstenes
AU652130B2 (en) * 1989-09-25 1994-08-18 University Of Utah Research Foundation Use of steroid hormones in compositions for inducing T cell lymphokine production
IE60458B1 (en) * 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates
IE900306A1 (en) * 1990-01-29 1991-07-31 Elan Corp Agent for use in the prevention, control or reversal of¹hypertension

Also Published As

Publication number Publication date
CA2117532A1 (en) 1993-09-02
US5527789A (en) 1996-06-18
EP0627921A1 (de) 1994-12-14
ES2146228T3 (es) 2000-08-01
DE69328771D1 (de) 2000-07-06
DE69328771T2 (de) 2000-12-07
EP0627921B1 (de) 2000-05-31
AU3731793A (en) 1993-09-13
JPH07504198A (ja) 1995-05-11
EP0627921A4 (de) 1995-03-01
WO1993016704A1 (en) 1993-09-02
AU676470B2 (en) 1997-03-13
CA2117532C (en) 2001-04-10

Similar Documents

Publication Publication Date Title
ATE193447T1 (de) Verfahren zur hemmung der karzinogenese durch behandlung mit dehydroepiandrosteron und dessen analoge
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
DE69310634T2 (de) Verwendung von Taxol zur Herstellung eines Arzneimittels zur Behandlung von Krebs
DE69320646D1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
PL310475A1 (en) Application of anticonvulsants in treating neuro-aids diseases
DE69910560D1 (de) Wasserlöslische prodrugs von 2,6-diisopropylphenol-analoga
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
DE3889536D1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
ZA953537B (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
WO1992012715A3 (en) The use of loperamide and related compounds for treatment of respiratory disease symptoms
ES2017808A6 (es) Un metodo para prepara una composicion para inhibir el crecimiento indeseado o patologico de celulas o tejidos.
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
NZ326345A (en) Composition containing diosgenin
LV11821A (lv) Savienojumu ar fosfonamida vai enola fosfata saiti pielietojums audzeju arstesanai
IL126159A (en) Pharmaceutical composition containing duloxetine for treating or preventing interstitial cystitis
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
BG102716A (en) Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline
DE69221725T2 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
GR3030856T3 (en) Use of somatostatin analogues for treating melanomas
EP0588873A4 (de) Behandlung von leberkrebs.
AU617622B2 (en) A method of treating chemical dependencies using sertraline
ATE121626T1 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
AU3750093A (en) Use of estriol for treating climacteric osteoporosis
EP0182569A3 (en) Use of 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyridoû1,2-a¨pyrimidine-3-carboxamide for the prevention and treatment of gastrointestinal damages

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties